𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of non-Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation

✍ Scribed by F. R. Appelbaum; E. D. Thomas; C. D. Buckner; R. A. Clift; H. J. Deeg; A. Fefer; P. E. Neiman; J. Sanders; P. Stewart; R. Storb; K. Sullivan

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
623 KB
Volume
1
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty patients with disseminated non-Hodgkin's lymphoma who failed conventional combination chemotherapy were treated with high-dose chemoradiotherapy and marrow transplantation from an HLA-identical sibling. Four patients remain alive in complete remission from 153 to 784 days after transplant. The reason for failure in eight cases was persistence or relapse of lymphoma. In the other eight cases, death was due to a complication of the transplant procedure including interstitial pneumonia, veno-occlusive disease of the liver, graft-versus-host disease, or infection. These results appear similar to those previously observed in patients with acute leukemia in relapse in that a small but significant proportion of patients with otherwise end-stage disease may achieve prolonged complete remission after intensive chemoradiotherapy and allogeneic marrow transplantation.

πŸ“œ SIMILAR VOLUMES

Allogeneic bone marrow transplantation f
Allogeneic bone marrow transplantation for high risk non-hodgkin's lymphoma during first complete remission
✍ Nademanee, A. P. ;Forman, S. J. ;Schmidt, G. M. ;Bierman, P. J. ;Snyder, D. S. ; πŸ“‚ Article πŸ“… 1987 πŸ› Springer-Verlag βš– 530 KB

Allogeneic bone marrow transplantation from histocompatible sibling donors was performed in six patients with extranodal involvement of high grade lymphoma during first complete remission. Five patients had lymphoblastic lymphoma and one had diffuse undifferentiated lymphoma. The cytoreductive/immun

Autologous bone marrow transplantation i
Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A southwest oncology group study
✍ Ruben Saez; Steve Dahlberg; Frederick R. Appelbaum; Robert J. Hartsock; Frederic πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 700 KB

## Abstract Patients with non‐Hodgkin's lymphoma (NHL) who fail conventional chemotherapy have a dismal outcome. Reports from single institutions utilizing high‐dose chemoradiotherapy plus Autologous Bone Marrow Transplantation (ABMT) in this setting suggest three‐year disease‐free survival between

Treatment of advanced non-Hodgkin's lymp
Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion
✍ Don V. Jackson Jr; Eugene H. Paschold; Charles L. Spurr; Hyman B. Muss; Fred Ric πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 532 KB

Twenty-five patients with a variety of histologic types of advanced non-Hodgkin's lymphoma refractory to previous chemotherapy were entered into a trial of vincristine infusion. Patients received 5-day courses of vincristine 0.25 mg/m2/day by continuous intravenous infusion after an initial 0.5 mg i

The treatment of non-Hodgkin's lymphoma
The treatment of non-Hodgkin's lymphoma
✍ Samuel Hellman; David S. Rosenthal; William C. Moloney; John T. Chaffey πŸ“‚ Article πŸ“… 1975 πŸ› John Wiley and Sons 🌐 English βš– 432 KB πŸ‘ 2 views

Much of the approach to evaluation and management of the non-Hodgkin's lymphomas has been modeled after Hodgkin's disease. However, as the name implies, they are quite different. The non-Hodgkin's lymphomas are a group of diseases and syndromes. These many different presentations, syndromes, and pos